Improved glycemic control currently relies on hybrid closed‐loop insulin delivery systems[2] that combine a continuous glucose monitoring device connected to an insulin pump delivering insulin at high glucose levels (hyperglycemia). The gene discussed is INS; the disease is Hyperglycemia.